New atypical antipsychotic for schizophrenia has ‘negligible’ weight effect

A new atypical antipsychotic medication that provides a sustained improvement of the symptoms of schizophrenia with negligible effect on patients’ metabolic parameters has been welcomed by Australian experts. Professor David Castle from Melbourne says the availability of Latuda (lurasidone HCl) on the PBS (from 1 November 2015) for the treatment of schizophrenia in adults has